US2011118191A1PendingUtilityA1

Crotoxin Administration for Cancer Treatment and Pain Relief

35
Individually held — no corporate assignee on recordPriority: Nov 14, 2009Filed: Nov 15, 2010Published: May 19, 2011
Est. expiryNov 14, 2029(~3.3 yrs left)· nominal 20-yr term from priority
Inventors:Paul Reid
C12Y 301/01004A61P 35/04A61K 38/465
35
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed is a method for treating cancer and/or pain using an intra-patient dose escalation procedure to deliver dosages of crotoxin.

Claims

exact text as granted — not AI-modified
1 . A method for treating cancer comprising administering to a cancer patient at least one Crotoxin dosage of from about 0.04 to about 0.32 mg/m 2 , the dosage being intravenously administered in an intra-patient dose escalation procedure, the intra-patient dose escalation procedure comprising consecutive administration of about 0.04 mg/m 2 /day for a 3-5 day treatment period, about 0.12 mg/m 2 /day for a 3-5 day treatment period, about 0.16 mg/m 2 /day for a 3-5 day treatment period, about 0.20 mg/m 2 /day for a 3-5 day treatment period, about 0.24 mg/m 2 /day for a 3-5 day treatment period, 0.28 mg/m 2 /day for a 3-5 day treatment period, and 0.32 mg/m 2 /day for a 3-5 day treatment period, wherein each successive dose escalation is conditioned upon the absence of dose-limiting toxicity from the previous dose. 
     
     
         2 . The method of  claim 1  wherein the intra-patient dose escalation procedure further comprises a two-day non-treatment period between each treatment period. 
     
     
         3 . The method of  claim 1  wherein the dosage is intravenously administered by saline drip. 
     
     
         4 . A method for treating pain in a patient comprising administering to the patient at least one Crotoxin dosage of from about 0.04 to about 0.32 mg/m 2 , the dosage being intravenously administered in an intra-patient dose escalation procedure, the intra-patient dose escalation procedure comprising consecutive administration of about 0.04 mg/m 2 /day for a 3-5 day treatment period, about 0.12 mg/m 2 /day for a 3-5 day treatment period, about 0.16 mg/m 2 /day for a 3-5 day treatment period, about 0.20 mg/m 2 /day for a 3-5 day treatment period, about 0.24 mg/m 2 /day for a 3-5 day treatment period, 0.28 mg/m 2 /day for a 3-5 day treatment period, and 0.32 mg/m 2 /day for a 3-5 day treatment period, wherein each successive dose escalation is conditioned upon the absence of dose-limiting toxicity from the previous dose. 
     
     
         5 . The method of  claim 4  wherein the pain is associated with cancer. 
     
     
         6 . The method of  claim 5  wherein the cancer is pancreatic cancer. 
     
     
         7 . The method of  claim 4  wherein the pain is associated with arthritis.

Join the waitlist — get patent alerts

Track US2011118191A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.